Meredith C. Henderson, PhD, Head, R&D, Provista Diagnostics, describes the dtectDx Breast test.
Meredith C. Henderson, PhD, Head, R&D, Provista Diagnostics, describes the dtectDxBreast test.
DtectDxBreast is essentially a blood test for the detection of breast cancer and is meant to be used in conjunction with mammography. With this test, Henderson says, information is available for a physician to make a decision regarding further imaging or biopsying.
DtectDxBreast is especially beneficial for women under 50 years, who tend to be underserved by mammography. The test is also beneficial, Henderson says, as it should not be affected by dense breast tissue or previous biopsy. If imaging is difficult or confounding in a patient, an empirical value from the dtectDxBreast test is still possible.
Clinical Pearls
PD-L1 Status Shapes Choice of Using Nivolumab in Upper GI Cancer
March 27th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed the issue of treating patients with upper gastrointestinal cancer with a PD-L1 composite positive score less than 5 with nivolumab vs chemotherapy alone, in the first article of a 2-part series.
Read More
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More